Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RITUXIMAB-ABBS Cause Malignant neoplasm progression? 20 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Malignant neoplasm progression have been filed in association with RITUXIMAB-ABBS. This represents 0.5% of all adverse event reports for RITUXIMAB-ABBS.

20
Reports of Malignant neoplasm progression with RITUXIMAB-ABBS
0.5%
of all RITUXIMAB-ABBS reports
19
Deaths
6
Hospitalizations

How Dangerous Is Malignant neoplasm progression From RITUXIMAB-ABBS?

Of the 20 reports, 19 (95.0%) resulted in death, 6 (30.0%) required hospitalization, and 4 (20.0%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RITUXIMAB-ABBS. However, 20 reports have been filed with the FAERS database.

What Other Side Effects Does RITUXIMAB-ABBS Cause?

Off label use (2,167) Intentional product use issue (273) Dyspnoea (208) Pain (205) Rheumatoid arthritis (202) Intentional dose omission (196) Fatigue (195) Drug ineffective (186) Hypertension (183) Infusion related reaction (183)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which RITUXIMAB-ABBS Alternatives Have Lower Malignant neoplasm progression Risk?

RITUXIMAB-ABBS vs RITUXIMAB-ARRX RITUXIMAB-ABBS vs RITUXIMAB-PVVR RITUXIMAB-ABBS vs RIVAROXABAN RITUXIMAB-ABBS vs RIVASTIGMINE RITUXIMAB-ABBS vs RIVOTRIL

Related Pages

RITUXIMAB-ABBS Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression RITUXIMAB-ABBS Demographics